Stormer that is a good question. Why are not the yamks all over...

Stormer that is a good question. Why are not the yamks all over it.

Firstly am surprised after the meeting where it was said that there will be a small discount and then they come up with 8 cents. After the previous announcements seemed like they knew the value of the opportunity and themselves fronting up money to then give shares away at 8 cents. Self interest with cheap shares possibly involved here after all the incentive options expired.
Say one thing do the opposite does not give trust . Add on top a failed Nasdaq listing does not give investors confidence.

Pulse is a disruptor . There is risk with no contracts, questionable corporate governance and a disaster of a annual report with all the debt investors would most likely have backed away as new funds would have been just paying of the debt.

The good news is that the clinchain funds and funding package has cleaned the balance sheet up. Directors coming onboard next year hopefully fixes governance issues. There is a runway now to show the value of this with deals.
There is a disconnect with winning industry awards and getting the pulse into the places where it starts to make money.
The CES 2023 was the biggest waste of time and money. There was no big bang as there were no contracts or investors that came from this. Should be doing CES 2024. Again questionable management decisions.

This is the opportunity now to get contracts, to show that the pulse is a disruptor and needed technology as we believe it is.From previous notes 1 clinic wants it immediately.........show us.... get it done.......
I think management are confident putting all the money on line, they see it, just market sees the other distractions instead of the opportunity.

SO Stormer to answer you question i think what is need now is contracts and then a shift in sentiment should occur as the disruptur starts to become the mainstream and could be a really quality re rate.
Really want to see some form of contarcts before the end of the capital raise closure.